Chimeric antigen receptor T cells against CD19 for multiple myeloma

New England Journal of Medicine

Volumn 373, Issue 11, 2015, Pages 1040-1047

  Garfall, Alfred L ^a,c   Maus, Marcela V ^a,c   Hwang, Wei Ting ^b,c   Lacey, Simon F ^b,c   Mahnke, Yolanda D ^b,c   Melenhorst, J Joseph ^b,c   Zheng, Zhaohui ^b,c   Vogl, Dan T ^a,c   Cohen, Adam D ^a,c   Weiss, Brendan M ^a,c   Dengel, Karen ^c   Kerr, Naseem D S ^c   Bagg, Adam ^b,c   Levine, Bruce L ^b,c   June, Carl H ^b,c   Stadtmauer, Edward A ^a,c  

^a Division of Hematology Oncology   (United States)

^b Department of Biostatistics and Epidemiology ^*  (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CARFILZOMIB; CD19 ANTIGEN; CISPLATIN; CLARITHROMYCIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ELOTUZUMAB; ETOPOSIDE; FERRITIN; FILGRASTIM; GAMMA INTERFERON; IMMUNOGLOBULIN A; INTERLEUKIN 6; LENALIDOMIDE; MELPHALAN; POMALIDOMIDE; T LYMPHOCYTE RECEPTOR; VORINOSTAT; CTL019 CHIMERIC ANTIGEN RECEPTOR; LYMPHOCYTE ANTIGEN RECEPTOR;

ADULT; ANOREXIA; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BONE MARROW BIOPSY; CANCER PROGNOSIS; CASE REPORT; DRUG MEGADOSE; FEBRILE NEUTROPENIA; FEMALE; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; FLUORESCENCE IN SITU HYBRIDIZATION; GASTROINTESTINAL TOXICITY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOGLOBULIN DEFICIENCY; KARYOTYPE; LYMPHOCYTE COUNT; MAINTENANCE THERAPY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NAUSEA; NEUTROPENIA; NEUTROPHIL COUNT; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STAPHYLOCOCCAL BACTEREMIA; THROMBOCYTOPENIA; TREATMENT RESPONSE; AUTOTRANSPLANTATION; BONE MARROW; CLINICAL TRIAL; IMMUNOLOGY; METABOLISM; PATHOLOGY; REMISSION;

ADULT; ANTIGENS, CD19; BONE MARROW; FEMALE; HUMANS; MULTIPLE MYELOMA; RECEPTORS, ANTIGEN, T-CELL; REMISSION INDUCTION; TRANSPLANTATION, AUTOLOGOUS;

EID: 84941312389     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1504542     Document Type: Article

References (19)

1. Maus MV, Grupp SA, Porter DL, June CH. Antibody-modified T cells: CARs take the front seat for hematologic malignancies. Blood 2014; 123: 2625-35.
2. Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptor- modified T cells in chronic lymphoid leukemia. N Engl J Med 2011; 365: 725-33.
3. Kalos M, Levine BL, Porter DL, et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med 2011; 3: 95ra73.
4. Maude SL, Frey N, Shaw PA, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med 2014; 371: 1507-17.
5. Grupp SA, Kalos M, Barrett D, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 2013; 368: 1509-18.
6. Tembhare PR, Yuan CM, Venzon D, et al. Flow cytometric differentiation of abnormal and normal plasma cells in the bone marrow in patients with multiple myeloma and its precursor diseases. Leuk Res 2014; 38: 371-6.
7. Hajek R, Okubote SA, Svachova H. Myeloma stem cell concepts, heterogeneity and plasticity of multiple myeloma. Br J Haematol 2013; 163: 551-64.
8. Durie BGM, Harousseau JL, Miguel JS, et al. International uniform response criteria for multiple myeloma. Leukemia 2006; 20: 1467-73.
9. Lee DW, Gardner R, Porter DL, et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood 2014; 124: 188-95.
10. Stadtmauer EA, Vogl DT, Luning Prak E, et al. Transfer of influenza vaccineprimed costimulated autologous T cells after stem cell transplantation for multiple myeloma leads to reconstitution of influenza immunity: results of a randomized clinical trial. Blood 2011; 117: 63-71.
11. Yaccoby S. The phenotypic plasticity of myeloma plasma cells as expressed by dedifferentiation into an immature, resilient, and apoptosis-resistant phenotype. Clin Cancer Res 2005; 11: 7599-606.
12. Kukreja A, Hutchinson A, Dhodapkar K, et al. Enhancement of clonogenicity of human multiple myeloma by dendritic cells. J Exp Med 2006; 203: 1859-65.
13. Fuhler GM, Baanstra M, Chesik D, et al. Bone marrow stromal cell interaction reduces syndecan-1 expression and induces kinomic changes in myeloma cells. Exp Cell Res 2010; 316: 1816-28.
14. Hideshima T, Mitsiades C, Ikeda H, et al. A proto-oncogene BCL6 is up-regulated in the bone marrow microenvironment in multiple myeloma cells. Blood 2010; 115: 3772-5.
15. Leung-Hagesteijn C, Erdmann N, Cheung G, et al. Xbp1s-negative tumor B cells and pre-plasmablasts mediate therapeutic proteasome inhibitor resistance in multiple myeloma. Cancer Cell 2013; 24: 289-304.
16. Gunderson AJ, Coussens LM. B cells and their mediators as targets for therapy in solid tumors. Exp Cell Res 2013; 319: 1644-9.
17. Affara NI, Ruffell B, Medler TR, et al. B cells regulate macrophage phenotype and response to chemotherapy in squamous carcinomas. Cancer Cell 2014; 25: 809-21.
18. Shalapour S, Font-Burgada J, Di Caro G, et al. Immunosuppressive plasma cells impede T-cell-dependent immunogenic chemotherapy. Nature 2015; 521: 94-8.
19. Rapoport AP, Stadtmauer EA, Aqui N, et al. Rapid immune recovery and graftversus-host disease-like engraftment syndrome following adoptive transfer of costimulated autologous T cells. Clin Cancer Res 2009; 15: 4499-507.